Zacks: Analysts Anticipate Prothena Co. PLC (NASDAQ:PRTA) Will Announce Quarterly Sales of $150,000.00

Equities research analysts expect Prothena Co. PLC (NASDAQ:PRTA) to post $150,000.00 in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Prothena’s earnings. The highest sales estimate is $200,000.00 and the lowest is $100,000.00. Prothena reported sales of $190,000.00 during the same quarter last year, which indicates a negative year over year growth rate of 21.1%. The company is expected to announce its next earnings results on Thursday, February 13th.

On average, analysts expect that Prothena will report full-year sales of $730,000.00 for the current year, with estimates ranging from $660,000.00 to $800,000.00. For the next fiscal year, analysts forecast that the firm will report sales of $23.35 million, with estimates ranging from $800,000.00 to $45.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Prothena.

Prothena (NASDAQ:PRTA) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. The firm had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.15 million. Prothena had a negative return on equity of 26.02% and a negative net margin of 10,450.00%.

A number of research firms have issued reports on PRTA. ValuEngine cut Prothena from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. Zacks Investment Research cut Prothena from a “buy” rating to a “hold” rating and set a $11.00 price objective for the company. in a report on Wednesday, October 23rd. BidaskClub upgraded Prothena from a “hold” rating to a “buy” rating in a report on Wednesday, December 4th. Finally, Evercore ISI upgraded Prothena from an “in-line” rating to an “outperform” rating in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $11.94.

PRTA stock traded down $0.11 during trading hours on Friday, reaching $12.85. 131,664 shares of the stock were exchanged, compared to its average volume of 237,829. The firm’s 50-day moving average is $10.72 and its 200-day moving average is $9.36. The company has a market cap of $517.06 million, a price-to-earnings ratio of -3.56 and a beta of 2.32. The company has a debt-to-equity ratio of 0.07, a current ratio of 12.88 and a quick ratio of 12.88. Prothena has a 12 month low of $6.71 and a 12 month high of $14.77.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Prothena by 0.5% in the 2nd quarter. BlackRock Inc. now owns 3,351,908 shares of the biotechnology company’s stock valued at $35,431,000 after acquiring an additional 17,619 shares in the last quarter. Orbimed Advisors LLC grew its holdings in shares of Prothena by 25.9% in the 2nd quarter. Orbimed Advisors LLC now owns 3,065,278 shares of the biotechnology company’s stock valued at $32,400,000 after acquiring an additional 630,000 shares in the last quarter. Great Point Partners LLC grew its holdings in shares of Prothena by 23.3% in the 3rd quarter. Great Point Partners LLC now owns 2,066,041 shares of the biotechnology company’s stock valued at $16,198,000 after acquiring an additional 389,791 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Prothena by 376.2% in the 3rd quarter. Millennium Management LLC now owns 1,228,476 shares of the biotechnology company’s stock valued at $9,631,000 after acquiring an additional 970,503 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of Prothena by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 813,376 shares of the biotechnology company’s stock valued at $8,597,000 after acquiring an additional 5,817 shares in the last quarter. Institutional investors own 93.97% of the company’s stock.

Prothena Company Profile

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.

Featured Story: Why is cost of goods sold important?

Get a free copy of the Zacks research report on Prothena (PRTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Prothena (NASDAQ:PRTA)

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.